未知生产厂商
ES16001 is an oral COVID-19 treatment candidate developed by Genencell, described as a new material-based new drug candidate extracted from the leaves of wild dampalsu trees, a native plant in Korea, developed jointly by Genencell and Kyunghee University's Biomedical Research Institute. South Korea's MFDS approved phase 2 and 3 clinical trials of ES16001 in 2021.
ES16001 is an oral COVID-19 treatment candidate developed by Genencell, described as a new material-based new drug candidate extracted from the leaves of wild dampalsu trees, a native plant in Korea, developed jointly by Genencell and Kyunghee University's Biomedical Research Institute. South Korea's MFDS approved phase 2 and 3 clinical trials of ES16001 in 2021.
Inhibits virus infection and replication, and inhibits host cell invasion and reactivation; expected to inhibit the receptor-binding domain binding activity of SARS-CoV-2, the virus that causes COVID-19, and to alleviate symptoms.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
